ロード中...
Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation fo...
保存先:
| 出版年: | Hepatol Commun |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5944590/ https://ncbi.nlm.nih.gov/pubmed/29761169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep4.1160 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|